Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Efficacy and Safety of Alectinib in Pediatric and Adult Patients with ALK-Altered Advanced Solid Tumors: a phase II TACKLE Trial (NCCH1712/MK003).

PURPOSE Anaplastic lymphoma kinase (ALK) alterations occur in a range of rare malignancies; however, prospective evidence supporting alectinib beyond lung cancer remains limited. We evaluated the activity and safety of alectinib in patients with advanced ALK-altered solid tumors. PATIENTS AND METHODS In this open-lab...

H. Okuma, A. Arakawa, Akihiro Hirakawa et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.